Nicox NDA for NCX 470 accepted for review in China
Nicox said its NCX 470 new drug application was accepted for review in China. The U.S. PDUFA date is the target date for FDA’s NDA review decision.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.